ArQule, Inc.

ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancer

Published in Proteomics Weekly, February 15th, 2010

ArQule, Inc. (Nasdaq: ARQL) announced the initiation of a Phase 2, single agent trial with ARQ 197 in germ cell tumors (GCT), including testicular and non-central nervous system (non-CNS) tumors, and a Phase 1/2 clinical trial designed to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer (CRC) who possess the wild-type form of the KRAS gene.

ARQ 197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase. The trials will be conducted by Daiichi Sankyo Pharma Development, a division of Daiichi Sankyo, Inc., the co-developer of ARQ 197 outside of certain...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly

Source: Proteomics Weekly (2010-02-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry